An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort.
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Howard I. Scher, Matthew R. Smith, Christopher Sweeney, Paul Gettys Corn, Christopher Logothetis, Nicholas J. Vogelzang, David C. Smith, Maha Hussain, Daniel J. George, Johann Sebastian De Bono, Celestia S. Higano, Eric Jay Small, Jonathan Goldin, Matthew S. Brown, Dana T. Aftab, Mojtaba Noursalehi, Aaron Weitzman, Ethan M. Basch
Institutions: Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, The US Oncology Network, Comprehensive Cancer Centers of Nevada, U-M Rogel Cancer Center, Duke University, Duke Cancer Institute, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Fred Hutch Cancer Center, University of California, San Francisco, University of California, Los Angeles, Exelixis (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2197462307